Osborne Partners Capital Management LLC Buys New Shares in Ralliant Corporation $RAL

Osborne Partners Capital Management LLC bought a new position in shares of Ralliant Corporation (NYSE:RAL) during the third quarter, according to its most recent Form 13F filing with the SEC. The fund bought 13,150 shares of the company’s stock, valued at approximately $575,000.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Dodge & Cox acquired a new position in shares of Ralliant in the second quarter valued at about $523,571,000. Viking Global Investors LP acquired a new stake in Ralliant during the second quarter worth approximately $257,200,000. State Street Corp acquired a new position in Ralliant in the 2nd quarter valued at $213,096,000. Flossbach Von Storch SE bought a new stake in shares of Ralliant during the 2nd quarter valued at $198,077,000. Finally, Norges Bank acquired a new stake in shares of Ralliant during the 2nd quarter worth $108,453,000.

Ralliant Price Performance

Shares of NYSE RAL opened at $53.79 on Thursday. The firm has a 50 day simple moving average of $50.49. The company has a current ratio of 1.49, a quick ratio of 1.03 and a debt-to-equity ratio of 0.39. Ralliant Corporation has a 1 year low of $40.70 and a 1 year high of $55.08. The company has a market cap of $6.07 billion and a price-to-earnings ratio of 42.35.

Ralliant (NYSE:RAL) last posted its earnings results on Wednesday, November 5th. The company reported $0.60 earnings per share for the quarter, topping analysts’ consensus estimates of $0.58 by $0.02. The business had revenue of $529.10 million for the quarter, compared to the consensus estimate of $519.14 million. Ralliant has set its Q4 2025 guidance at 0.620-0.680 EPS.

Ralliant Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, December 23rd. Investors of record on Monday, December 8th were issued a $0.05 dividend. This represents a $0.20 dividend on an annualized basis and a yield of 0.4%. The ex-dividend date was Monday, December 8th. Ralliant’s dividend payout ratio is presently 15.75%.

Wall Street Analysts Forecast Growth

RAL has been the topic of a number of recent analyst reports. Weiss Ratings reissued a “hold (c)” rating on shares of Ralliant in a research note on Monday, December 29th. Citigroup upgraded Ralliant from a “neutral” rating to a “buy” rating and upped their price objective for the stock from $53.00 to $61.00 in a research report on Monday, December 8th. Royal Bank Of Canada boosted their target price on Ralliant from $45.00 to $52.00 and gave the stock a “sector perform” rating in a research note on Friday, November 7th. Oppenheimer raised their price target on shares of Ralliant from $55.00 to $60.00 and gave the company an “outperform” rating in a research note on Monday, December 15th. Finally, Truist Financial initiated coverage on shares of Ralliant in a research report on Friday, December 12th. They set a “buy” rating and a $62.00 price objective for the company. Six equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $58.00.

Ralliant Company Profile

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.